TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Unternehmens-codeTMDX
Name des UnternehmensTransmedics Group Inc
IPO-datumMay 02, 2019
Gegründet am2018
CEODr. Waleed H. Hassanein, M.D.
Anzahl der mitarbeiter728
WertpapierartOrdinary Share
GeschäftsjahresendeMay 02
Addresse200 Minuteman Road
StadtANDOVER
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl01810
Telefon19785520900
Websitehttps://www.transmedics.com/
Unternehmens-codeTMDX
IPO-datumMay 02, 2019
Gegründet am2018
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten